CLAIMS

1. A compound having the structural formula (I):



(I)

or a pharmaceutically acceptable form thereof,

wherein

R^1 is H or halogen;

R^2 is H or halogen;

R^3 is C_{1-4} alkyl and R^4 is OC(O)-R^7, wherein R^7 is a substituted or unsubstituted aniline, or

R^3 and R^4, together with the carbon atoms they are bound to, form a 5-membered dioxolane substituted with W-R^6, wherein W is a single bond or -phenyl-Q-, Q is selected from CH_2, O, S, S(O), $S(O)_2$, NH and NCH_3, and R^6 is a substituted or unsubstituted aniline; and

R^5 is $NR^{5a}R^{5b}$ or CH_2R^{5c},

each of R^{5a} and R^{5b} is independently selected from H and C_{1-6} alkyl, or R^{5a} and R^{5b}, together with the N atom they are bound to, form a 4- to 7-membered, unsubstituted or substituted heterocyclic ring; and

R^{5c} is H, halogen or O-C_{1-3} alkyl.

2. The compound of claim 1, wherein R^4 is OC(O)-R^7, having the structural formula (II):



(II)

3. The compound of claim 2, having the structural formula (II[a]):



(II[a])

wherein

each of R^{7a}, R^{7b} and R^{7c} is selected from H and $NR^{7x}R^{7y}$, provided that only one of R^{7a}, R^{7b} and R^{7c} is $NR^{7x}R^{7y}$ and each of the others is H;

each of R^{7x} and R^{7y} is independently selected from R, R^{7r} and L^7-R^{7z}, provided that when one of R^{7x} and R^{7y} is L^7-R^{7z} or R^{7r}, the other is R;

L^7 is a linker;

R^{7r} is $(C=O)$-O-$(CH_2)_i$-R^{7v} or $(C=O)$-$(CH_2)_j$-R^{7v};

R^{7v} is R, OR, NHR, NR_2, an aryl group or an amino acid;

i is 0, 1, 2, 3, 4, 5 or 6;

j is 0, 1, 2, 3, 4, 5 or 6;

R^{7z} comprises a functional or reactive group; and

R is H or a C_1-C_6 alkyl.

4. The compound of any one of claims 1-3, wherein R^3 is an alkyl.

5. The compound of claim 4, wherein R^3 is methyl.

6. The compound of claim 1, wherein R^3 and R^4, together with the carbon atoms they are bound to, form a 5-membered dioxolane substituted with W-R^6, having the structural formula:



.

7. The compound of claim 6, wherein W is a single bond, having the structural formula (III):



.

(III)

8. The compound of claim 7, having the structural formula (III^a):



.

(III^a)

wherein

each of R^{6a}, R^{6b} and R^{6c} is selected from H and $NR^{6x}R^{6y}$, provided that only one of R^{6a}, R^{6b} and R^{6c} is $NR^{6x}R^{6y}$ and each of the others is H;

each of R^{6x} and R^{6y} is independently selected from R, R^{6r} and L^6-R^{6z}, provided that when one of R^{6x} and R^{6y} is L^6-R^{6z} or R^{6r}, the other is R;

L^6 is a linker;

R^{6r} is (C=O)-O-$(CH_2)_p$-R^{6v} or (C=O)-$(CH_2)_q$-R^{6v};

R^{6v} is R, OR, NHR, NR_2, an aryl group or an amino acid;

p is 0, 1, 2, 3, 4, 5 or 6;

q is 0, 1, 2, 3, 4, 5 or 6;

R^{6z} comprises a functional or reactive group; and

R is H or a C_1-C_6 alkyl.

9. The compound of claim 7 or 8, wherein R^6 has the *S*- configuration.

10. The compound of claim 7 or 8, wherein R^6 has the *R*- configuration.

11. The compound of claim 6, wherein W is -phenyl-Q-.

12. The compound of claim 11, wherein Q is CH_2, having the structural formula (III^b):



(III^b)

wherein

each of $R^{6a'}$, $R^{6b'}$ and $R^{6c'}$ is selected from H and $NR^{6x'}R^{6y'}$, provided that only one of $R^{6a'}$, $R^{6b'}$ and $R^{6c'}$ is $NR^{6x'}R^{6y'}$ and each of the others is H;

each of $R^{6x'}$ and $R^{6y'}$ is independently selected from R, $R^{6r'}$ and $L^{6'}$-$R^{6z'}$, provided that when one of $R^{6x'}$ and $R^{6y'}$ is $L^{6'}$-$R^{6z'}$ or $R^{6r'}$, the other is R';

$L^{6'}$ is a linker;

$R^{6r'}$ is (C=O)-O-$(CH_2)_p$-$R^{6v'}$ or (C=O)-$(CH_2)_q$-$R^{6v'}$;

$R^{6v'}$ is R, OR, NHR, NR_2, an aryl group or an amino acid;

p is 0, 1, 2, 3, 4, 5 or 6;

q is 0, 1, 2, 3, 4, 5 or 6;

$R^{6z'}$ comprises a functional or reactive group; and

R is H or a C_1-C_6 alkyl.

13. The compound of claim 11 or 12, wherein the carbon atom in 5-membered dioxolane linked to W-R^6 has the *S*- configuration.

14. The compound of claim 11 or 12, wherein the carbon atom in 5-membered dioxolane linked to W-R^6 has the *R*- configuration.

15. The compound of any one of claims 3-14, wherein L^6 or L^7, or $L^{6'}$, when present, is a noncleavable linker.

16. The compound of any one of claims 3-14, wherein L^6 or L^7, or $L^{6'}$, when present, is a cleavable linker.

17. The compound of any one of claims 1-16, wherein R^5 is $NR^{5a}R^{5b}$.

18. The compound of any one of claims 1-16, wherein R^5 is CH_2R^{5c}.

19. The compound of any one of claims 1-18, wherein each of R^1 and R^2 is H or F.

20. A compound selected from:















































wherein each of R^1 and R^2 is independently H or halogen,

or a pharmaceutically acceptable form thereof.

21. An immunoconjugate comprising a compound of any one of claims 1-20 covalently conjugated to an antigen binding moiety.

22. An immunoconjugate having the structural formula (IV):



(IV)

or a pharmaceutically acceptable form thereof,

wherein

Ab represents an antigen binding moiety;

R^1 is H or halogen;

R^2 is H or halogen;

R^3 is C_{1-4} alkyl;

R^5 is $NR^{5a}R^{5b}$ or CH_2R^{5c},

each of R^{5a} and R^{5b} is independently selected from H and C_{1-6} alkyl, or R^{5a} and R^{5b}, together with the N atom they are bound to, form a 4- to 7-membered heterocyclic ring; and

R^{5c} is H, halogen or O-C_{1-3} alkyl;

R^{7x} is H or C_{1-6} alkyl;

L^{Ab} is a linker; and

n is an integer in the range of 1 to about 20.

23. An immunoconjugate having the structural formula (V) or (VI):



(V)

or



(VI)

or a pharmaceutically acceptable form thereof,

wherein

Ab represents an antigen binding moiety;

Q is selected from CH_2, O, S, S(O), $S(O)_2$, NH and NCH_3;

R^1 is H or halogen;

R^2 is H or halogen;

R^5 is $NR^{5a}R^{5b}$ or CH_2R^{5c},

each of R^{5a} and R^{5b} is independently selected from H and C_{1-6} alkyl, or R^{5a} and R^{5b}, together with the N atom they are bound to, form a 4- to 7-membered heterocyclic ring; and

R^{5c} is H, halogen or O-C_{1-3} alkyl;

R^{6x} is H or C_{1-6} alkyl;

L^{Ab} is a linker; and

n is an integer in the range of 1 to about 20.

24. The immunoconjugate of claim 23, wherein Q is CH_2, having the structural formula of:



.

25. The immunoconjugate of claim 23, wherein Q is CH_2, having the structural formula of:



.

26. The immunoconjugate of any one of claims 22-25, wherein each of R^1 and R^2 is H or F.

27. The immunoconjugate of any one of claims 22-26, wherein R^5 is $NR^{5a}R^{5b}$.

28. The immunoconjugate of any one of claims 22-26, wherein R^5 is CH_2R^{5c}.

29. The immunoconjugate of any one of claims 21-28, wherein Ab is an antibody.

30. A pharmaceutical composition comprising an immunoconjugate of any of claims 21-29, and a pharmaceutically acceptable excipient, carrier or diluent.

31. Use of a compound of any one of claims 1-20 for the manufacture of a medicament in the treatment of an inflammatory disorder.
32. Use of an immunoconjugate of any one of claims 21-29 or the pharmaceutical composition of claim 30 for the manufacture of a medicament in the treatment of an inflammatory disorder.
33. A compound of any one of claims 1-20 for use as a medicament.
34. An immunoconjugate of any one of claims 21-29 or the pharmaceutical composition of claim 30 for use as a medicament.